44 Matching Annotations
  1. Apr 2022
  2. Mar 2022
    1. ReconfigBehSci on Twitter: ‘@alexdefig are you really going to claim that responses to the introduction of passports on uptake across 4 other countries are evidentially entirely irrelevant to whether or not passports are justified or not?’ / Twitter. (n.d.). Retrieved 31 March 2022, from https://twitter.com/SciBeh/status/1444358068280565764

    1. Lauring, A. S., Tenforde, M. W., Chappell, J. D., Gaglani, M., Ginde, A. A., McNeal, T., Ghamande, S., Douin, D. J., Talbot, H. K., Casey, J. D., Mohr, N. M., Zepeski, A., Shapiro, N. I., Gibbs, K. W., Files, D. C., Hager, D. N., Shehu, A., Prekker, M. E., Erickson, H. L., … Self, W. H. (2022). Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: Prospective observational study. BMJ, 376, e069761. https://doi.org/10.1136/bmj-2021-069761

  3. Feb 2022
    1. APPG on Coronavirus. (2022, January 18). 🗣Dr.Claire Steves continued: “Looking in the national core studies, from cohort studies across the UK we’ve looked at 10 different longitudinal studies. Our best estimates are that about 5% of middle aged people are experiencing long term.. 27/ #APPGCoronavirus #LongCovid [Tweet]. @AppgCoronavirus. https://twitter.com/AppgCoronavirus/status/1483453895061999618

  4. Dec 2021
  5. Nov 2021
  6. Oct 2021
    1. Pozzetto, B., Legros, V., Djebali, S., Barateau, V., Guibert, N., Villard, M., Peyrot, L., Allatif, O., Fassier, J.-B., Massardier-Pilonchéry, A., Brengel-Pesce, K., Yaugel-Novoa, M., Denolly, S., Boson, B., Bourlet, T., Bal, A., Valette, M., Andrieu, T., Lina, B., … Trouillet-Assant, S. (2021). Immunogenicity and efficacy of heterologous ChadOx1/BNT162b2 vaccination. Nature, 1–9. https://doi.org/10.1038/s41586-021-04120-y

    1. Tartof, S. Y., Slezak, J. M., Fischer, H., Hong, V., Ackerson, B. K., Ranasinghe, O. N., Frankland, T. B., Ogun, O. A., Zamparo, J. M., Gray, S., Valluri, S. R., Pan, K., Angulo, F. J., Jodar, L., & McLaughlin, J. M. (2021). Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: A retrospective cohort study. The Lancet, 398(10309), 1407–1416. https://doi.org/10.1016/S0140-6736(21)02183-8

  7. Sep 2021
    1. Hippisley-Cox, J., Coupland, C. A., Mehta, N., Keogh, R. H., Diaz-Ordaz, K., Khunti, K., Lyons, R. A., Kee, F., Sheikh, A., Rahman, S., Valabhji, J., Harrison, E. M., Sellen, P., Haq, N., Semple, M. G., Johnson, P. W. M., Hayward, A., & Nguyen-Van-Tam, J. S. (2021). Risk prediction of covid-19 related death and hospital admission in adults after covid-19 vaccination: National prospective cohort study. BMJ, 374, n2244. https://doi.org/10.1136/bmj.n2244

  8. Aug 2021
  9. Jun 2021
    1. Li, X., Ostropolets, A., Makadia, R., Shoaibi, A., Rao, G., Sena, A. G., Martinez-Hernandez, E., Delmestri, A., Verhamme, K., Rijnbeek, P. R., Duarte-Salles, T., Suchard, M. A., Ryan, P. B., Hripcsak, G., & Prieto-Alhambra, D. (2021). Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: Multinational network cohort study. BMJ, 373, n1435. https://doi.org/10.1136/bmj.n1435

  10. May 2021
    1. Eric Topol. (2021, May 1). Downgrading the concern on B.1.617, the poorly named ‘double mutant’—98% effectiveness of mRNA vaccine in an Israeli outbreak @CT_Bergstrom https://t.co/tGbuwPUmAL —Lab studies: Minimal immune evasion, expected full protection from vaccine @GuptaR_lab https://t.co/AIp24G0ROK https://t.co/AK20UWlDBD [Tweet]. @EricTopol. https://twitter.com/EricTopol/status/1388539223230140422

  11. Mar 2021
  12. Dec 2020
  13. Jun 2020
  14. May 2020
  15. Apr 2020
    1. Adams, E. R., Anand, R., Andersson, M. I., Auckland, K., Baillie, J. K., Barnes, E., Bell, J., Berry, T., Bibi, S., Carroll, M., Chinnakannan, S., Clutterbuck, E., Cornall, R. J., Crook, D. W., Silva, T. D., Dejnirattisai, W., Dingle, K. E., Dold, C., Eyre, D. W., … Sanchez, V. (2020). Evaluation of antibody testing for SARS-Cov-2 using ELISA and lateral flow immunoassays. MedRxiv, 2020.04.15.20066407. https://doi.org/10.1101/2020.04.15.20066407

  16. Aug 2016